Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16819025 | 0.88 | CNR2 (0.31) | CNR2 | |
| SCHEMBL16819024 | 0.88 | CNR2 (0.31) | CNR2 | |
| SCHEMBL1260916 | 0.88 | CNR1 (0.32) | CNR1CNR2METAP2 | |
| SCHEMBL2171477 | 0.85 | ALDH1A1 (0.32) | CNR1CNR2 | |
| SCHEMBL7945504 | 0.85 | ALDH1A1 (0.32) | CNR1CNR2 | |
| SCHEMBL2172887 | 0.85 | ALDH1A1 (0.32) | CNR1CNR2 | |
| SCHEMBL19263184 | 0.85 | ALDH1A1 (0.32) | CNR1CNR2 | |
| SCHEMBL20751965 | 0.80 | CNR2 (0.32) | CNR2 | |
| SCHEMBL19174733 | 0.80 | MAPT (0.34) | — | |
| SCHEMBL19375705 | 0.79 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| WO-2015100145-A1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | CNR1 3932/4885CNR2 4655/4885METAP2 1260/4885 |
| US-10030033-B2 | Synthesis of an antiviral compound | EIF2AK2, MAVS, SARS1 | CNR1 3932/4885CNR2 4655/4885METAP2 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.